Hormonal
GLP-1 receptor agonists (specifically semaglutide) produce substantial, sustained weight loss and improve health status in patients with heart failure with preserved ejection fraction (HFpEF).
For patients with HFpEF and obesity, GLP-1 agonists like semaglutide are a potent tool for weight loss and improving heart function. This treatment, combined with dietary advice, can lead to significant health improvements. Discuss this option with your cardiologist, especially if other weight loss methods have been difficult to sustain.
In STEP-HFpEF (n = 529) the GLP-1 receptor agonist semaglutide reduced weight by 10.7 %, improved health status, reduced a hierarchical composite endpoint, improved exercise function, and reduced inflammation and NT-proBNP [5].
Why this rating
Based on a large randomized trial (STEP-HFpEF, n=529) with clear positive outcomes, though long-term clinical event data is still pending.
Source
Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?
Matthew M.Y. Lee et al. · Current Heart Failure Reports · 2023
DOI 10.1007/s11897-023-00637-7
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →